Choice of adjuvant drug therapy on the basis of the molecular classification of breast cancer

Por N. S. Besova
Publicado em 2014-07-01

Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer

Por N. S. Besova
Publicado em 2020-07-01

Nivolumab as a representative of immune checkpoint inhibitors in late-line treatment for disseminated gastric cancer

Por N. S. Besova
Publicado em 2021-08-01

A case of effective disease control of advanced gastric cancer following ramucirumab plus FOLFIRI in second line treatment in clinical practice

Por T. A. Titova, N. S. Besova, E. A. Artamonova
Publicado em 2020-12-01

Clinical example of long-term control of disseminated signet-ring cell carcinoma of the stomach against the background of chemotherapy of the second line of treatment in combinatio...

Por T. A. Titova, N. S. Besova, E. V. Artamonova
Publicado em 2019-12-01

Clinical example of enhancing efficacy of paclitaxel by combining it with ramuchirumabin in the second-line chemotherapy of disseminated gastric cancer

Por T. A. Titova, E. V. Artamonova, N. S. Besova
Publicado em 2019-06-01

A COMBINATION OF TAXOTERE, DOXORUBICIN, CYCLOPHOSPHOMIDE IN ADJUVANT CHEMOTHERAPY OF OPERABLE BREAST CANCER GRANULOCYTE COLONY-STIMULATING FACTORS PRIMARY PROPHYLAXIS

Por N. S. Besova, V. A. Gorbunova, I. V. Poddubnaya, N. P. Makarenko
Publicado em 2014-09-01

Case report of partial response on second line with Ramucirumab and FOLFIRI in treatment of 74 year old male with metastatic HER2-negative gastric adenocarcinoma

Por N. S. Besova, T. A. Titova, A. E. Kalinin, V. A. Shalenkov, I. S. Stilidi
Publicado em 2021-08-01

Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer

Por T. A. Titova, N. S. Besova, V. A. Gorbunova, R. N. Nasyrova, A. A. Fedenko
Publicado em 2018-07-01

Results of the use of trastuzumab combined with different chemotherapy regimens in first-line treatment of HER2-positive disseminated gastric cancer

Por N. S. Besova, T. A. Titova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova
Publicado em 2019-06-01

ACUTE MYOCARDIAL INFARCTION IN THE ABSENCE OF CORONARY ARTERY OBSTRUCTION – A COMPLICATION OF ANTICANCER THERAPY WITH CAPECITABINE

Por E. A. Kolomiets, I. A. Kurmukov, Sh. R. Kashiya, N. S. Besova, S. V. Limareva, A. P. Sandomirskaya
Publicado em 2017-12-01

Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disse...

Por T. A. Titova, N. S. Besova, V. A. Gorbunova, Yu. P. Kuvshinov, A. A. Filatov, A. F. Ketsba, A. A. Fedenko
Publicado em 2018-07-01

Ramucirumab with paclitaxel or FOLFIRI as second-line treatment in docetaxel-pre-treated patients with metastatic gastric cancer in real-world setting

Por N. S. Besova, Т. А. Titova, А. А. Tryakin, Е. V. Artamonova, Е. S. Obarevich, D. L. Stroyakovskiy, О. Е. Kalinin, I. S. Stilidi
Publicado em 2021-06-01

Vozmozhnosti ispol'zovaniya taksotera pri razlichnykh solidnykh opukholyakh

Por V A Gorbunova, N F Orel, T A Borisova, N S Besova, A F Marenich, M B Bychkov, S V Khokhlova, D R Naskhletashvili
Publicado em 2002-12-01

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer

Por N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi
Publicado em 2019-06-01

REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCE...

Por N. S. Besova, T. A. Titova, V. A. Gorbunova, O. O. Gordeeva, A. A. Tryakin, A. V. Snegovoy, R. Yu. Nasyrova, A. A. Rumyantsev, E. A. Voroshilova, E. V. Artamonova
Publicado em 2017-11-01

THE USE OF PACLITAXEL IN CHEMORADIOTHERAPY OF PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL: A PILOT STUDY

Por S. S. Gordeev, V. A. Gorbunova, S. I. Tkachev, V. V. Glebovskaya, N. S. Besova, Yu. E. Suraeva, M. Yu. Fedyanin, V. A. Ivanov, V. S. Anan’ev, A. G. Malikhov, A. O. Rasulov
Publicado em 2017-01-01

Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or card...

Por N. S. Besova, T. A. Titova, E. V. Trusilova, V. A. Gorbunova, A. A. Tryakin, O. O. Gordeeva, A. A. Rumyantsev, R. Yu. Nasyrova, L. G. Zhukova, A. V. Snegovoy, E. V. Artamonova, L. V. Manzyuk, A. A. Fedenko
Publicado em 2018-07-01

Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA t...

Por N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi
Publicado em 2020-07-01

Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia

Por N. S. Besova, T. A. Titova, E. V. Artamonova, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukal’chuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, A. A. Tryakin, I. S. Stilidi
Publicado em 2019-12-01